FYI: OXGN - early ASCO datapoints coming in:
OXGN OXiGENE announces phase II Combretastatin A4 Phosphate / CA4P study with paclitaxel and carboplatin shows safety, anti-tumor activity (4.80 +0.23)
Co announces the publication of two abstracts in the 2007 Annual Meeting program distributed this afternoon at the Annual Meeting of the American Society of Clinical Oncology in Chicago, IL. The first abstract reports for the first time full data from a randomized Phase II trial of Combretastatin A4 Phosphate / CA4P in combination with paclitaxel and carboplatin. In the abstract, lead author Dr. Wallace L. Akerley of the Huntsman Cancer Institute reports that the two dose regimens of CA4P studied, 45 mg/m2 and 63 mg/m2 in combination with paclitaxel and carboplatin, were well tolerated, demonstrated anti-tumor activity and reduced tumor blood flow by 46% and 19%, respectively. Tumor responses were observed and were similar between both dose groups, and the best overall response through cycle 6 was three partial responses and six stable disease responses as measured by RECIST criteria. The second abstract reports for the first time initial data from early dosing cohorts in a Phase I study of OXi4503 in patients with advanced solid tumors. Lead author Dr. Daniel M. Patterson of the Mount Vernon Cancer Centre indicates that while the study had not yet reached maximum tolerated dose and recruitment is ongoing, the data to date suggest that OXi4503 is tolerated at doses up to 5 mg/m2 without dose-limiting toxicity.
AI
